More Robust Data Should Be Required Before Drugs Fully Approved
Abstract: Many cancer drugs are converted from accelerated to regular approval by the FDA despite a lack of proof that patients will reap clinically meaningful benefits from their use. Researchers suggest the FDA withhold regular approval of a drug until its manufacturer implements a trial design that can robustly demonstrate its benefit to patients.